Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track
Executive Summary
Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.